Pfizer

This study tested a new mRNA vaccine to prevent shingles (herpes zoster) in healthy adults aged 50 to 85. The vaccine was compared to the approved shingles shot. The trial was terminated early, so results are limited. The goal was to check safety and how well the vaccine triggers…

This study tested a new drug called sasanlimab (which helps the immune system fight cancer) combined with other targeted therapies in people with advanced non-small cell lung cancer. The trial was stopped early, but researchers were checking for safety and whether tumors shrank. …

This study looks at the long-term safety of inclacumab in people with sickle cell disease who have already taken the drug in a previous study. It tracks side effects and how often pain crises happen. The goal is to see if the drug remains safe over time.

This study looked at how well the medicine abrocitinib works for adults with moderate to severe atopic dermatitis (eczema). Researchers tracked 112 people for up to 12 months to see if their skin cleared or improved. The study was stopped early, but the goal was to understand rea…

This study looked at the long-term safety of the drug voxelotor in 162 people with sickle cell disease who had already taken it in earlier studies. The main goal was to track any side effects. The study was stopped early, but the results help doctors understand how safe voxelotor…

This study tested a drug called voxelotor in children aged 2 to 15 with sickle cell disease who had slightly abnormal blood flow in the brain. The goal was to see if the drug could improve blood flow and reduce stroke risk. The trial was stopped early, but the results may still p…

This early-phase study tested a new medicine called PF-07921585, given alone or with another drug (sasanlimab), in adults with advanced solid tumors like lung, bladder, kidney, skin, head and neck, or colorectal cancer. The goal was to check safety and how the body handles the dr…

This study tested a gene therapy called fordadistrogene movaparvovec in 10 boys with early-stage Duchenne muscular dystrophy. The goal was to see if it was safe and could help their muscles produce a shortened version of the missing protein, dystrophin. The trial was terminated e…

This study tested an experimental drug called PF-06823859 in adults with lupus that affects the skin. The goal was to see if the drug could reduce skin inflammation and improve symptoms. The study was stopped early and only enrolled 8 people, so results are limited.

This study tested an experimental drug (PF-06873600) taken by mouth, alone or with hormone therapy, in people with advanced breast or ovarian cancers. About 155 participants took the drug once or twice daily for at least 7-8 months. The main goals were to check safety and see if …

This study looked at the long-term safety of the drug voxelotor in people with sickle cell disease who had already taken it in a previous study. About 179 participants were enrolled to track side effects and complications like pain crises. The study was terminated early, but the …

This early-phase study tested a new drug (PF-07265028) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, stomach, and head/neck cancers. The goal was to find the safest dose and see if the drug shrinks tumors. The study was stopped early, and…

This study tested an oral drug called sisunatovir for treating RSV in adults who are not hospitalized but have a high risk of severe illness. Participants took either the drug or a placebo for 5 days. The study was terminated early after enrolling only 16 people, so results are l…

This study tested an experimental oral drug, PF-07054894, in 44 adults aged 18-75 with mild to severe ulcerative colitis. The goal was to see if it could safely reduce inflammation and improve symptoms. The trial was terminated early, so results are limited.

This study compares two combinations of drugs for people with advanced melanoma that has a specific genetic change (BRAF V600E/K) and has worsened after prior anti-PD-1 therapy. Participants receive either a three-drug combo (encorafenib, binimetinib, and pembrolizumab) or a two-…

This early-stage study tested a new drug, PF-08046037, alone or with another drug (sasanlimab) in people with advanced lung, head and neck, skin, or pancreatic cancers. The goal was to check safety and how the body processes the drug. Only 8 people took part before the study was …

This early-phase study tested a new medicine, PF-08046032, alone or with another drug (sasanlimab) in 6 adults with advanced lymphomas or solid tumors that had spread or stopped responding to standard treatments. The main goals were to check safety and find the right dose. The st…

This study looked at combining two experimental drugs (maplirpacept and glofitamab) after a single dose of obinutuzumab for adults with diffuse large B-cell lymphoma that has come back or not responded to at least two prior treatments. Participants could not have a stem cell tran…

This study followed 60 adults with rheumatoid arthritis in Colombia to see how well they stuck to their etanercept injections using a smart device called Smartclic. Researchers checked medical records and pharmacy data over 40 weeks to measure adherence, disease activity, and phy…

This study tested a new three-drug combination for people with a type of blood cancer called diffuse large B-cell lymphoma that came back or didn't respond to prior treatment. Participants could not have a stem cell transplant or CAR-T therapy. The goal was to find a safe and eff…

This study tested a new drug, elranatamab, combined with other cancer treatments for people with multiple myeloma that had returned or not responded to at least three prior therapies. The goal was to find the best dose and see if the combination helps control the disease. The stu…

This study looked at whether a full or half dose of the medicine pantoprazole could keep the esophagus healed in children aged 1 to 17 who had healed from a type of severe heartburn called erosive esophagitis. The study planned to follow 43 children for 24 weeks, but it was stopp…

This early-phase study tested a new drug called PF-07284890, alone or with another drug (binimetinib), in people with advanced solid tumors that have a specific BRAF V600 mutation, including those with brain tumors. The main goals were to check safety, how the drug moves through …

This study was designed to check the long-term safety of the drug GBT021601 in people with sickle cell disease who had already taken it in a previous study. It included 47 participants aged 6 months and older. The study was terminated early, so results are limited.

This early-stage study tested a new drug called PF-07826390, given alone or with another drug (sasanlimab), in people with advanced solid tumors like lung, colon, kidney, and ovarian cancers. The goal was to check safety, find the right dose, and see if the drug shrinks tumors. O…

This study aimed to see how well the drug tofacitinib (Xeljanz) works for people with moderate to severe ulcerative colitis in everyday medical practice in Switzerland. Researchers planned to track symptoms, quality of life, and a gut inflammation marker over 8 weeks. The study w…

This early-stage study tested a new drug called PF-08046031 in 11 adults with advanced melanoma or other solid tumors that had spread or no longer responded to standard treatments. The main goal was to check the drug's safety and side effects. The study was terminated early, so r…

This study looked at the safety and amount of a new medicine called sisunatovir in the blood of infants and children up to 5 years old with RSV lung infections. About 10 children took part, receiving either the drug or a placebo. The study was stopped early, but the results will …

This study tested a single dose of a gene therapy called PF-06939926 in 23 people with Duchenne muscular dystrophy (DMD), both those who could still walk and those who could not. The main goal was to check safety and side effects over one year. The trial was stopped early, but re…

This study followed 265 people with sickle cell disease who were taking Oxbryta to see how the drug worked in everyday life, outside of a controlled trial. Researchers tracked changes in blood counts, organ function, and complications like pain crises over up to 5 years. The goal…

This early-stage study tested a new experimental drug (PF-07820435) alone or with another drug (sasanlimab) in people with advanced solid tumors like lung, skin, and kidney cancers. The goal was to check safety and find the right dose. Only 9 people took part before the study was…

This study tested an experimental drug, PF-07258669, to help older adults (60-90 years) who are at risk of malnutrition or losing weight without trying. The goal was to see if the drug is safe and how it affects the body. The trial was stopped early after enrolling only 7 partici…

This study tested an experimental drug called Ponsegromab to see if it could improve symptoms and quality of life in adults with heart failure. Participants received either the drug or a placebo as a shot under the skin every four weeks for about 9 months. The study was terminate…

This study tested an experimental medicine called PF-07899895 in healthy adults aged 18 to 65. The goal was to check how safe the drug is and how much of it gets into the blood after taking it by mouth. Participants received either the drug or a placebo and stayed at the clinic f…

This early-stage study tested a new medicine called PF-07314470 in 23 healthy adults to see if it was safe and how the body handles it. Participants received either the medicine or a placebo by injection under the skin. The study was terminated early, so results are limited.

This study observed how the antibiotic ceftazidime-avibactam was used in everyday hospital practice in China for serious infections like pneumonia and abdominal infections. Researchers planned to enroll about 450 patients but the study was terminated early. The goal was to see ho…

This study checks the long-term safety and effects of an experimental gene therapy called fordadistrogene movaparvovec in people with Duchenne muscular dystrophy who already received it in an earlier study. Participants will be followed for 10 years with yearly visits. The goal i…

This study aimed to see how effective the 2024-2025 Pfizer COVID-19 vaccine is at preventing symptomatic COVID-19 in real-world settings. It planned to compare vaccinated and unvaccinated people who got tested at CVS MinuteClinics. However, the study was terminated early and only…